Alzamend Neuro

Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company, which engages in the manufacture of pharmaceutical products. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical company, which focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.

ATLANTA--(BUSINESS WIRE)---- $ALZN #Alzamend--Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement.

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

ATLANTA--(BUSINESS WIRE)---- $ALZN #15_to_1_stock_reversal--Alzamend Neuro Announces Reverse Stock Split.

Alzamend Neuro Announces Reverse Stock Split

Biora Therapeutics Inc

PAVmed

Developing groundbreaking drugs and devices entails high costs, uncertain regulatory approval, and lucrative revenues. Those factors and more culminate to create a sector filled with dozens of biotech stocks that have 10X potential, or better.

3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024

eFFECTOR Therapeutics Inc

Synlogic

Turning $1,000 into $10,000 in a year in the stock market is undoubtedly a lofty goal. Make no bones about it, it's not particularly likely to happen.

3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year

LAVAL, Québec--(BUSINESS WIRE)-- #Altasciences--Altasciences is proud to support Alzamend Neuro, Inc. (Alzamend) in advancing a novel treatment for dementia related to Alzheimer's disease (Alzheimer's).

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

LAS VEGAS--(BUSINESS WIRE)---- $ALZN #ALZN--Ault Alliance Announces Alzamend Neuro Initiated Its Phase I/IIA Trial for Immunotherapy Vaccine ALZN002 to Treat Mild to Moderate Alzheimer's Disease

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

LAS VEGAS--( BUSINESS WIRE )--BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”), today announced that the Company is considering undertaking an exchange offer (the “Offer”) whereby it would offer debt in the form of notes in exchange for between $50 and $75 million of common stock. If the Company proceeds with the Offer, the Company presently intends to commence the Offer in early 2023 and its terms will be contained in an Offer to Exchange. If the Offer proceeds, the Company intends to apply to list the notes on the NYSE American Exchange. Until such time as the notes are listed on the NYSE American, trading in the notes will occur on the OTC.

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

NEW YORK, NY / ACCESSWIRE / November 22, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Alzamend Neuro. Toni had the pleasure of recently conducting the Interview with Stephan Jackman, Chief Executive Officer and Director Alzamend Neuro, Inc. (NASDAQ:ALZN).

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

BitNile Holdings

LAS VEGAS--( BUSINESS WIRE )--BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”), reported its financial results for the third quarter ended September 30, 2022 on its Form 10-Q filed with the Securities and Exchange Commission.

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

LAS VEGAS--(BUSINESS WIRE)---- $ALZN #ALZN--BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”) today announced that Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder, major depressive disorder and post-traumatic stress disorder, received a “study may proceed” letter from the U.S. Food and Drug Admi

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

Acumen Pharmaceuticals

Ginkgo Bioworks Holdings

NeuroSense Therapeutics Ltd

Penny stocks to buy [or avoid] after Biogen Alzheimer's news. The post 4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes

ATLANTA--(BUSINESS WIRE)---- $ALZN #Alzamend--Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Applied Genetic Technologies

Ampio Pharmaceuticals Inc

Bird Rides

Curis

DURECT

Each of these penny stocks with 1,000% upside potential could rise 10X in the future for investors with a high risk tolerance. The post 6 Penny Stocks With 1,000% Upside Potential appeared first on InvestorPlace.

6 Penny Stocks With 1,000% Upside Potential

Drive Shack

Zomedica

Which penny stocks are you watching right now? The post 3 Penny Stocks to Add to Your Watchlist This Coming Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Add to Your Watchlist This Coming Week

Southwestern Energy

Uranium Energy

Can penny stocks continue to show positive momentum in 2022? The post Are These Penny Stocks Worth Buying Right Now?

Are These Penny Stocks Worth Buying Right Now?

Sphere 3D

GSX Techedu Inc.

Can penny stocks continue to show momentum next year? The post Here's 3 Top Penny Stocks For Your January Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Here's 3 Top Penny Stocks For Your January Watchlist

Alzamend reported positive results from its phase 1 study using AL001 for the treatment of patients with Alzheimer's Disease.

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Alzamend Neuro Inc (NASDAQ: ALZN) has posted positive topline data from its Phase 1 trial for AL001 as an oral treatment for dementia-related to Alzheimer's disease. The trial was designed to determine the pharmacokinetics, safety, and tolerability of AL001 and target doses for a planned Phase 2 study in Alzheimer's patients.

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

The company hopes to advance the standard of care for people with dementia.

Why Alzamend Neuro Stock Soared Today

Arbutus Biopharma

CTI BioPharma

Katapult Holdings

Progenity

5 penny stocks analysts say are a buy right now with hefty price targets. The post Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets

ALZN stock has been on the move higher in anticipation that Alzamend Neuro will soon share the results from one of its key medication studies. The post ALZN Stock Alert: What Is Going on With Alzamend Neuro Today?

ALZN Stock Alert: What Is Going on With Alzamend Neuro Today?

Cellectar BioSciences

Mustang Bio

ReShape Lifesciences

X4 Pharmaceuticals Inc

5 penny stocks to watch this week The post Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week

Check these penny stocks out for your watchlist this week The post Are These Penny Stocks on Your Watchlist This Week? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are These Penny Stocks on Your Watchlist This Week?

Asensus Surgical

Which biotech penny stocks are you watching this month? The post Best Biotech Penny Stocks to Buy in November?

Best Biotech Penny Stocks to Buy in November? 3 to Watch Now

Today, investors in preclinical biotech company Alzamend Neuro and ALZN stock are seeing impressive gains of more than 25% currently. The post ALZN Stock: Why Is Little-Known Alzamend Neuro Gaining Today?

News for Alzamend Neuro Stock (ALZN)